keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma; hodgkin's

keyword
https://www.readbyqxmd.com/read/28928855/association-between-extranodal-natural-killer-t-cell-lymphoma-and-hepatitis-b-viral-infection-a-case-control-study
#1
Kefeng Wang, Hang Yang, Wenjun He, Yi Xia, Zhongjun Xia, Su Li, Huiqiang Huang, Zhiming Li, Panpan Liu, Wenqi Jiang
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare subtype of lymphoma that is often associated with poor clinical prognosis. Several studies have shown that hepatitis B virus (HBV) infection may be associated with increased risk of B-cell non-Hodgkin lymphoma; however, because of the rarity of ENKTL, little is known about its association with HBV. Our study aimed to assess whether HBV infection was associated with increased odds of ENKTL. We conducted a hospital-based case-control study including 417 ENKTL cases and 488 age- and sex-matched subjects with nonmalignant diseases unrelated to HBV infection...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28927453/employment-status-and-health-related-quality-of-life-among-hodgkin-lymphoma-survivors-results-based-on-data-from-a-major-treatment-center-in-hungary
#2
Ferenc Magyari, Karolina Kósa, Roland Berecz, Anna Illés, Zsófia Miltényi, Zsófia Simon, Árpád Illés
BACKGROUND: Due to risk and response adapted treatment strategies, more than 80% of newly diagnosed classical Hodgkin lymphoma (HL) patients can be cured, and become long-term survivors. However, a high proportion of survivors suffer from treatment-related long-term side effects such as secondary malignancy, organ failure, persistent fatigue and psychological distress. The aim of this study was to evaluate psychological distress and its risk factors among our HL survivors. METHODS: One hundred sixty-three (50% female) adult HL survivors were contacted between January 1, 2012 and march 31, 2015 in our outpatient centre...
September 19, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28927145/bcl2-ki-67-index-predict-survival-in-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma
#3
Yun-Long Tang, Yan Zhou, Ling-Ling Cheng, Yong-Zhong Su, Chun-Bin Wang
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. BCL2 apoptosis regulator (BCL2) and marker of proliferation Ki-67 (Ki-67) are established prognostic markers, which have traditionally been assessed separately in DLBCL. However, no studies have evaluated the prognostic value of the combination of BCL2 and Ki-67 index. Thus, the present study aimed to analyze the prognostic value of combination of these two markers. Immunohistochemical analysis was used to assess the expression of BCL2 and Ki-67 in 274 cases of DLBCL...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28926410/outcomes-for-hiv-associated-diffuse-large-b-cell-lymphoma-in-the-modern-cart-era
#4
Caroline Besson, Remi Lancar, Sophie Prevot, Michele Algarte-Genin, Pierre Delobel, Fabrice Bonnet, Marie-Caroline Meyohas, Marialuisa Partisani, Lucie Oberic, Jean Gabarre, Cécile Goujard, François Boue, Paul Coppo, Regis Costello, Houria Hendel-Chavez, Nawel Mekerri, Gabriella Dos Santos, Christian Recher, Richard Delarue, Rene-Olivier Casasnovas, Yassine Taoufik, Nicolas Mounier, Dominique Costagliola
OBJECTIVE: Non-Hodgkin's lymphoma (NHL) remains among the most frequent malignancies in persons living with HIV (PLWHIV). Survival among patients with HIV-associated diffuse large B-cell lymphoma (DLBCL), the most frequent NHL subtype, has improved markedly in recent years. We aimed to analyze characteristics and outcomes of DLBCL in HIV-infected patients in the era of modern combined antiretroviral therapy (cART). DESIGN: PLWHIV with lymphoma were prospectively enrolled in the French ANRS-CO16 Lymphovir cohort between 2008 and 2015...
September 18, 2017: AIDS
https://www.readbyqxmd.com/read/28925583/decreasing-incidence-of-cancer-after-liver-transplantation-a-nordic-population-based-study-over-three-decades
#5
A Nordin, F Åberg, E Pukkala, C R Pedersen, H H Storm, A Rasmussen, W Bennet, M Olausson, H Wilczek, B-G Ericzon, S Tretli, P-D Line, T H Karlsen, K M Boberg, H Isoniemi
Cancer remains one of the most serious long-term complications after liver transplantation (LT). Data for all adult LT patients between 1982 and 2013 was extracted from the Nordic Liver Transplant Registry. Through linkage with respective national cancer-registry data, we calculated standardized incidence ratios (SIRs) based on country, sex, calendar time, and age-specific incidence rates. Altogether 461 cancers were observed in 424 individuals out the 4246 LT patients during a mean 6.6-year follow-up. The overall SIR was 2...
September 19, 2017: American Journal of Transplantation
https://www.readbyqxmd.com/read/28923647/is-cytomegalovirus-surveillance-necessary-for-patients-with-low-reactivation-risk-in-an-autologous-hematopoietic-cell-transplantation-setting
#6
A H Kaya, E Tekgunduz, S Akpinar, H Batgi, F Bekdemir, O Kayikci, S Namdaroglu, B U Ulu, M S Dal, M K Cakar, S Korkmaz, F Altuntas
BACKGROUND: In an autologous hematopoietic cell transplantation (AHCT) setting, routine cytomegalovirus (CMV) surveillance is not indicated except in high-risk situations. On the other hand, some studies reported increased CMV reactivation in AHCT setting as a result of incorporation of novel agents into treatment algorithms, such as bortezomib and rituximab. We retrospectively analyzed CMV reactivation and infection rates in patients with no high-risk features, who were treated with AHCT...
October 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28923211/nivolumab-and-pembrolizumab-monoclonal-antibodies-against-programmed-cell-death-1-pd-1-that-are-interchangeable
#7
REVIEW
Vinay Prasad, Victoria Kaestner
Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1). Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance. These drugs have earned a series of FDA approvals for melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), urothelial cancer, classical Hodgkin lymphoma, and renal cell cancer...
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28922087/preexisting-cardiovascular-risk-and-subsequent-heart-failure-among-non-hodgkin-lymphoma-survivors
#8
Talya Salz, Emily C Zabor, Peter de Nully Brown, Susanne Oksberg Dalton, Nirupa J Raghunathan, Matthew J Matasar, Richard Steingart, Andrew J Vickers, Peter Svenssen Munksgaard, Kevin C Oeffinger, Christoffer Johansen
Purpose The use of anthracycline chemotherapy is associated with heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL). We aimed to understand the contribution of preexisting cardiovascular risk factors to HF risk among NHL survivors. Methods Using Danish registries, we identified adults diagnosed with aggressive NHL from 2000 to 2010 and sex- and age-matched general-population controls. We assessed HF from 9 months after diagnosis through 2012. We used Cox regression analysis to assess differences in risk for HF between survivors and general population controls...
September 18, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28921451/distribution-of-malignant-lymphomas-in-the-anterior-mediastinum-a-single-institution-study-of-76-cases-in-japan-1997-2016
#9
Akiko Miyagi Maeshima, Hirokazu Taniguchi, Tomotaka Suzuki, Sayako Yuda, Kosuke Toyoda, Nobuhiko Yamauchi, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Dai Maruyama, Yukio Kobayashi, Kensei Tobinai
We analyzed the distribution of tumors and lymphomas of the anterior mediastinum diagnosed between 1997 and 2016 at the National Cancer Center Hospital, Japan. The median age of 283 patients with anterior mediastinal tumors was 48 (range 6-84) years, and 143 (51%) were male. The incidence of tumors was as follows: thymoma, 34%; thymic carcinoma, 16%; primary mediastinal large B-cell lymphoma (PMBL), 13%; germ cell tumors, 10%; classical Hodgkin lymphoma (CHL), 9%; thymic cyst, 7%; metastatic tumors, 3%; T lymphoblastic leukemia/lymphoma (T-LBL), 2%; other lymphomas, 3%; and others, 3%...
September 18, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28921160/gp2013-a-rituximab-biosimilar
#10
Hannah A Blair
GP2013 is the second biosimilar of the reference monoclonal anti-CD20 antibody rituximab to be approved in the EU. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. GP2013 has similar physicochemical and pharmacodynamic properties to those of reference rituximab, and the pharmacokinetic biosimilarity of the agents has been shown in patients with RA...
September 18, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28920509/diagnosis-of-hyponatremia-and-increased-risk-of-a-subsequent-cancer-diagnosis-results-from-a-nationwide-population-based-cohort-study
#11
Louise Holland-Bill, Christian Fynbo Christiansen, Dóra Körmendiné Farkas, Frede Donskov, Jens Otto L Jørgensen, Henrik Toft Sørensen
BACKGROUND: Hyponatremia has recently been associated with subsequent cancer risk. This population-based nationwide study assessed whether the diagnosis of hyponatremia can predict a cancer diagnosis within most common cancers. MATERIAL AND METHODS: Using Danish medical registries, we identified 16,220 patients with a first-time diagnosis of hyponatremia, without a cancer diagnosis, from January 2006 through November 2013. We quantified the relative risk of a subsequent cancer diagnosis by standardized incidence ratios (SIRs), comparing observed cancer incidence among patients diagnosed with hyponatremia to that expected, based on national cancer incidence during that period...
September 18, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28919770/swollen-lymph-nodes-may-not-be-clinical-manifestations-of-chronic-myeloid-leukemia-case-report-and-revision-of-literature
#12
Zhihe Liu, Siyun Li, Ou Bai
We present here the case of a 33-year-old Chinese female patient with synchronous double primary malignant tumors (chronic myeloid leukemia [CML] and classic Hodgkin lymphoma). This patient was admitted to our hospital because of bilateral cervical lymph node enlargement and recurrent fever for 2 weeks. The complete blood cell count revealed white blood cell counts of 18.2×10(9)/L, hemoglobin of 9.6 g/dL, and platelet counts of 1,547×10(9)/L. Chromosome karyotype analysis demonstrated that t(9;22)(q34;q11) was positive in all 20 cells examined...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28916317/presence-of-human-herpesvirus-8-hhv-8-dna-sequences-in-patients-with-lymphoproliferative-diseases-and-chronic-blood-disorders
#13
Hossein Keyvani, Mohammad Hadi Karbalaie Niya, Maryam Esghaei, Farah Bokharaei Salim, Seyed Hamid Reza Monavari
OBJECTIVE: Human herpesvirus 8 (HHV-8) is the causative agent of Kaposi's sarcoma (KS), but it has also been associated with different hematologic malignancies, including plasmablastic lymphoma, Multicentric Castleman's disease (MCD), primary effusion lymphoma (PEL) and various atypical lymphoproliferative disorders. Patients with underlying lymphoproliferative diseases and chronic blood disorders who become infected with this virus are at risk for human malignancies. This small study reported the frequency of human herpesvirus -8 in 81 Iranian patients with lymphoproliferative disorders for estimation of possible factors affecting malignancy...
September 12, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/28915427/breast-lymphoma-in-a-patient-with-b-cell-non-hodgkin-lymphoma-a-case-report-study
#14
Spyridon Marinopoulos, Panagiotis Safioleas, Lamprini Skorda, Eleni Vassilopoulou, Flora Zagouri, Maria Sotiropoulou, Peter Drakakis, Constantine Dimitrakakis
INTRODUCTION: Breast involvement in Non Hodgkin Lymphoma is a rare entity as it accounts for 2.2% of all extranodal lymphomas. PRESENTATION OF CASE: A 59-year-old woman was referred to our Breast Unit because of two nodules of the right breast newly discovered during her annual mammography. Moreover, during the physical examination, a red-brown itchy lump of the scalp was discovered. The punch biopsies of the scalp lesion and ultrasound-guided core biopsies of both nodules of the right breast, revealed the presence of diffuse large B-cell Non Hodgkin Lymphoma in all tissue specimen sites...
September 7, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28915338/neurocognitive-psychosocial-and-quality-of-life-outcomes-in-adult-survivors-of-childhood-non-hodgkin-lymphoma
#15
Matthew J Ehrhardt, Daniel A Mulrooney, Chenghong Li, Malek J Baassiri, Kari Bjornard, John T Sandlund, Tara M Brinkman, I-Chan Huang, Deo Kumar Srivastava, Kirsten K Ness, Leslie L Robison, Melissa M Hudson, Kevin R Krull
BACKGROUND: Children with non-Hodgkin lymphoma (NHL) undergo treatment with central nervous system-directed therapy, the potentially neurotoxic effects of which have not been reported in NHL survivors. METHODS: NHL survivors (n = 187) participating in the St. Jude Lifetime Cohort who were 10 or more years from their diagnosis and were 18 years old or older underwent neurocognitive, emotional distress (Brief Symptom Inventory 18), and health-related quality of life (HRQOL) assessments (36-Item Short Form Health Survey)...
September 15, 2017: Cancer
https://www.readbyqxmd.com/read/28914619/there-are-no-magic-bullets-in-hematopathology-even-immunostains-for-cd20-and-cd3-can-get-you-into-trouble
#16
Judith A Ferry
Immunohistochemistry is a powerful tool for the diagnosis and subclassification of hematolymphoid neoplasms. However, the expression of certain markers is not always as expected, and unusual patterns of staining can lead to misdiagnosis. CD20 and CD3 are our most commonly used markers for identification of B cells and T cells, respectively, and they almost always yield reliable, specific staining. This discussion focuses on diagnostic pitfalls related to the use of immunohistochemistry for CD20 and CD3 in hematopathology, and specifically on diagnostic challenges that arise when (1) CD20 is not expressed in B-cell lymphomas, when (2) CD20 is expressed in plasma cell neoplasms and T-cell lymphomas, and when (3) CD3 is expressed in B-cell lymphomas and Hodgkin lymphoma...
September 13, 2017: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/28914567/chemotherapy-free-triple-combination-of-obinutuzumab-venetoclax-and-idasanutlin-antitumor-activity-in-xenograft-models-of-non-hodgkin-lymphoma
#17
Frank Herting, Thomas Friess, Pablo Umaña, Steven Middleton, Christian Klein
No abstract text is available yet for this article.
September 15, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28912991/t-cell-histiocyte-rich-large-b-cell-lymphoma-presenting-as-hemophagocytic-lymphohistiocytosis-an-uncommon-presentation-of-a-rare-disease
#18
Uroosa Ibrahim, Gwenalyn Garcia, Amina Saqib, Shafinaz Hussein, Qun Dai
T cell histiocyte rich large B cell lymphoma (THRLBCL) is a rare subtype of non-Hodgkin's lymphoma characterized by malignant B cells with reactive T lymphocytes. The pathophysiology is thought to involve cytokine-mediated evasion of T cell immune response by malignant B cells. It usually presents at an advanced stage with extranodal involvement. An extremely unusual manifestation of the disease is hemophagocytic lymphohistiocytosis (HLH) which is a hyperinflammatory disorder. We present a case of a 43-year-old male who presented with recurrent fever and recent radiologic imaging showing splenomegaly and right inguinal lymphadenopathy...
2017: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/28912397/-combination-therapy-of-immune-checkpoint-inhibitors
#19
Shigehisa Kitano
Recently, monotherapies of immune checkpoint inhibitor have been approved for some malignant tumors such as advanced melanoma, non-small cell lung cancer, renal cell cancer, Hodgkin lymphoma, head and neck cancer in Japan. As the next step, to aim improvement of the clinical benefit, development of combination immunotherapies including immune checkpoint inhibitors are ongoing. In this chapter, recent strategies of clinical development of combination immunotherapy are described.
September 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28912173/secondary-malignant-neoplasms-progression-free-survival-and-overall-survival-in-patients-treated-for-hodgkin-lymphoma-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#20
Dennis A Eichenauer, Ingrid Becker, Ina Monsef, Nicholas Chadwick, Vitaliana de Sanctis, Massimo Federico, Catherine Fortpied, Alessandro M Gianni, Michel Henry-Amar, Peter Hoskin, Peter Johnson, Stefano Luminari, Monica Bellei, Alessandro Pulsoni, Matthew R Sydes, Pinuccia Valagussa, Simonetta Viviani, Andreas Engert, Jeremy Franklin
Treatment intensification to maximize disease control and reduced-intensity approaches to minimize the risk of late sequelae have been evaluated in newly diagnosed Hodgkin lymphoma. The influence of these interventions on the risk of secondary malignant neoplasms, progression-free survival and overall survival is reported in the present meta-analysis based on individual patient data from 9498 patients treated within 16 randomized controlled trials for newly diagnosed Hodgkin lymphoma between 1984 and 2007. Secondary malignant neoplasms were meta-analyzed using Peto's method as time-to-event outcomes...
September 14, 2017: Haematologica
keyword
keyword
20697
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"